PE4S223 - Management of Lipid Disorders 01 Sep 2021 - 31 Aug 2027 | Version 2

Associated Module Information

Module Code: PE4S223
Module Title: Management of Lipid Disorders
Faculty: Faculty of Life Sciences and Education
Faculty Group: Allied Health and Chiropractic
Faculty Sub Group: Clinical Services
Module Leader: Karl New
Module Team:
First Intended Intake: SEP 2021 Final Year of Intake: 2026
Date Closed:
Credit Value: 20 Credit Level: 7
Language: English
Percentage of Module Taught in Welsh: 0
Equivalent Module:
HECOS codes: 100260 - healthcare science
HECOS Code Weighting: 100

Document Version Information

Version 2
Valid From 01 Sep 2021
Valid To 31 Aug 2027

Module Aims

To critically understand the management of inherited dyslipidaemias, with a particular focus on familial hypercholesterolemia. Also triglyceride, its metabolism and management.

Content Summary

Management strategies for lipid disorders. Specific non-pharmacological interventions for lipid disorders as well as current and emerging pharmacological therapies will be evaluated.

Learning and Teaching Methods

Activity Type Hours
Independent Study 100
Directed Study 100
Total Hours Selected 200

Learning Outcomes

# Learning Outcome
LO1 Demonstrate a critical understanding of the management of lipid disorders.
LO2 Critically appraise the potential role of novel therapies in the management of lipid disorders.

Module Requisites

N/A

Assessment Criteria

Assessment Category Assessment Type Description Duration Word Count Weight (%) Best of? Pass Mark
Synchronous Online Assessment Time-constrained assessment (Online) 1 End of Module examination relating to Management of Lipid Disorders 60 N/A 30 No 40
Asynchronous Assessment Self Reflective Assessment 1 Reflective Journal 0 600 10 No 40
Asynchronous Assessment Project 1 Completion of an individual project relating to Management of Lipid Disorders 0 N/A 20 No 40
Asynchronous Assessment Case study 1 Case based scenarios and discussion forum relating to Management of Lipid Disorders 0 N/A 40 No 40

Assessment Matrix

Assessment Type Learning Outcomes
LO1 LO2
Time-constrained assessment (Online) 1 ✔ ✔
Self Reflective Assessment 1 ✔ ✔
Project 1 ✔ ✔
Case study 1 ✔ ✔

Reading List

Gudzune, K.A., Monroe, A.K., Sharma, R., Ranasinghe, P.D., Chelladurai, Y. and Robinson, K.A., (2014). Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Annals of internal medicine, 160(7), pp.468-476.
http://annals.org/article.aspx?articleid=1828554

Abd, T.T. and Jacobson, T.A., (2011). Statin-induced myopathy: a review and update. Expert opinion on drug safety, 10(3), pp.373-387.
https://www.researchgate.net/profile/Thura_Harfi/publication/49856004_Statin-induced_myopathy_A_review_and_update/links/5757248708ae05c1ec16cf9a.pdf

Handelsman, Y. and Lepor, N.E., 2018. PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review. Journal of the American Heart Association, 7(13), p.e008953.

Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., Roden, M., Stein, E., Tokgözoglu, L., Nordestgaard, B.G. and Bruckert, E., 2015. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. European heart journal, 36(17), pp.1012-1022.